|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Celgene_Corporation
gptkb:Myokardia
|
|
gptkbp:CEO
|
Giovanni Caforio
|
|
gptkbp:employees
|
30,000+
|
|
gptkbp:founded
|
1887
|
|
gptkbp:founder
|
gptkb:John_Myers
gptkb:William_McLaren_Bristol
|
|
gptkbp:headquarters
|
gptkb:New_York_City
gptkb:United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bristol-Myers Squibb Co.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:notableFeature
|
gptkb:Abraxane
gptkb:Atezolizumab
gptkb:Nivolumab
gptkb:Carfilzomib
gptkb:Tisagenlecleucel
gptkb:Zeposia
gptkb:Cemiplimab
gptkb:Durvalumab
gptkb:Lisocabtagene_maraleucel
gptkb:Opdivo
gptkb:Ruxolitinib
gptkb:Dabrafenib
gptkb:Belantamab_mafodotin
gptkb:Ixazomib
gptkb:Orencia
gptkb:Tafasitamab
Nexavar
Reblozyl
Eliquis
Yervoy
Trametinib
Lenvatinib
Pomalyst
Bortezomib
Elotuzumab
Blinatumomab
Ibrutinib
Luspatercept
Mavacamten
Isunakinra
|
|
gptkbp:partnerships
|
gptkb:NantKwest
|
|
gptkbp:products
|
drugs
|
|
gptkbp:research_areas
|
oncology
fibrosis
immunology
cardiovascular
|
|
gptkbp:revenue
|
$46.4 billion (2020)
|
|
gptkbp:stockExchange
|
BMY
|
|
gptkbp:subsidiary
|
gptkb:Bristol-Myers_Squibb_Foundation
|
|
gptkbp:website
|
www.bms.com
|